4号创新：丙型肝炎（视频）的突破

克利夫兰诊所超过100的顶尖专家在未来的一年里，在未来的一年里，重塑医疗保健的创新。这些都是他们的答案- 2014大创新为10。

美国400万人感染丙型肝炎，治疗方案在过去的三年里有了很大的改善。

直到2011，没有被证明的药物治疗的患者没有回应传统的治疗方法，这种肝病。那一年，两个新的药物telaprevir和boceprevir克利夫兰诊所的10大创新名单和改变患者的前景。今年，另一个有前途的选择使名单：sofosbuvir，第一个全口服丙型肝炎的治疗。

更短，更安全，更容易忍受

Sofosbuvir is moving through the final stages of FDA approval。 Its promise includes the highest cure rates ever, reduced treatment time and fewer side effects。

Its promise includes the highest cure rates ever, reduced treatment time and fewer side effects。

This medication would be the first of a new generation of hepatitis C drugs called direct-acting antivirals (DAA)。 DAAs can improve what for many has been a very difficult treatment regimen — one that can take up to 48 weeks and requires injections of interferon, a drug that is difficult to tolerate。

More important, DAAs can improve treatment response rates to 90 percent or higher。 Sofosbuvir — and other DAAs in the pipeline — also are more tolerable and safer。

Even better, they reduce the treatment length to 12 weeks。

以前的创新

下一个创新

看到所有10个创新

（注：转载时请注明复诊网）